Corporate profile
Biocortech is a biopharmaceutical company committed to the discovery and development of new treatments for psychiatric disorders, including depression, bipolar disorders, schizophrenia, and cognitive deficits. We have proprietary assays and technologies to identify biomarkers and develop compounds that can safely and effectively treat these diseases. We have a strong clinical advisory group and drug development capabilities, enabling us to move diagnostic platforms and drugs into humans quickly and efficiently.
Targeted Therapeutic Area: Depression
Depression is a fast-growing health care issue affecting over 50 million people in developed countries. Despite extensive activity in the field, depression still represents an area of significant unmet medical need. About 40% of patients do not initially respond to available treatments, and 10%-30% show complete resistance to drug therapy. Even effective treatments induce side effects and require several weeks to be effective. Finally, many antidepressants have recently generated safety concerns, some of them being associated with suicidal behavior. These needs are driving the development of innovative treatments and therapeutic strategies, which could reach sales of more than $2.5B per year.
Biocortech Technologies
Clinical Development Program :
Small molecule that treats hypo-functionality of the prefrontal cortex in depressed patients. Clinical data in treatment resistant depressed patients.
Technology Platforms:
EDIT:Measuring changes in RNA editing of the serotonin 5-HT2C and glutamate receptors as biomarkers/drug targets.
TOP:Drug screening for reactivation of deficient pathways in the prefrontal cortex.
Business strategy
Biocortech is part of a worldwide effort to discover and develop new drugs for psychiatric diseases. Although traditionally an arena dominated by large pharmaceutical laboratories, psychiatric disease has also created tremendous growth opportunities for biotech companies. Biocortech's goal is to develop diagnostics and new drug therapies for psychiatric diseases, based on its proprietary technologies, working independently as well as through strategic alliances with pharmaceutical companies. Biocortech intends to become a world leader in treatments for depression, and particularly for the even bigger unmet needs in treatment-resistant depression.